Development of antimalarial histone deacetylase inhibitors [ 2015 - 2018 ]

Research Grant

Researchers: Prof David Fairlie (Principal investigator) ,  Prof Katherine Andrews

Brief description Human histone deacetylases (HDACs) are enzymes clinically validated as targets for cancer chemotherapy. Different HDAC enzymes are important for survival of infectious organisms, such as protozoan Plasmodium parasites that cause malaria. This project will develop promising drug leads that kill the parasites without damaging human cells through preclinical studies in mice towards a future clinical trial for the treatment of malaria in humans.

Funding Amount $AUD 573,676.63

Funding Scheme Development Grants

Notes Development Grant